Evidence map›Paper›PMID 29889893›Full record

ArticlePloS one2018

MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT.

Anna Keravnou, Marios Ioannides, Charalambos Loizides, Kyriakos Tsangaras, Achilleas Achilleos, Petros Mina, Elena Kypri, Michael D Hadjidaniel, Maria Neofytou, Skevi Kyriacou and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Anna KeravnouTranslational Genetics Team, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Marios IoannidesNIPD Genetics Ltd., Nicosia, Cyprus.
Charalambos LoizidesNIPD Genetics Ltd., Nicosia, Cyprus.
Kyriakos TsangarasNIPD Genetics Ltd., Nicosia, Cyprus.
Achilleas AchilleosNIPD Genetics Ltd., Nicosia, Cyprus.
Petros MinaNIPD Genetics Ltd., Nicosia, Cyprus.
Elena KypriNIPD Genetics Ltd., Nicosia, Cyprus.
Michael D HadjidanielTranslational Genetics Team, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Maria NeofytouTranslational Genetics Team, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.ORCID 0000-0001-7159-3278
Skevi KyriacouNIPD Genetics Ltd., Nicosia, Cyprus.
Carolina SismaniDepartment of Cytogenetics and Genomics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
George KoumbarisNIPD Genetics Ltd., Nicosia, Cyprus.
Philippos C PatsalisTranslational Genetics Team, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.ORCID 0000-0003-0662-460X
Medicover Genetics (Cyprus)Cyprus Institute of Neurology and Genetics · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation is the most characterized epigenetic process exhibiting stochastic variation across different tissues and individuals. In non-invasive prenatal testing (NIPT) fetal specific methylated regions can potentially be used as biomarkers for the accurate detection of fetal aneuploidies. The aim of this study was the investigation of inter-individual methylation variability of previously reported fetal-specific markers and their implementation towards the development of a novel NIPT assay for the detection of trisomies 13, 18, and 21. Methylated DNA Immunoprecipitation (MeDIP) combined with in-solution targeted enrichment followed by NGS was performed in 29 CVS and 27 female plasma samples to assess inter-individual methylation variability of 331 fetal-specific differentially methylated regions (DMRs). The same approach was implemented for the NIPT of trisomies 13, 18 and 21 using spiked-in (n = 6) and pregnancy samples (n = 44), including one trisomy 13, one trisomy 18 and four trisomy 21. Despite the variability of DMRs, CVS samples showed statistically significant hypermethylation (p<2e-16) compared to plasma samples. Importantly, our assay correctly classified all euploid and aneuploid cases without any false positive results (n = 44). This work provides the starting point for the development of a NIPT assay based on a robust set of fetal specific biomarkers for the detection of fetal aneuploidies. Furthermore, the assay's targeted nature significantly reduces the analysis cost per sample while providing high read depth at regions of interest increasing significantly its accuracy.

Indexed as

Prenatal CareAneuploidyBiomarkersChromosomes, Human, Pair 18Chromosomes, Human, Pair 21DNADNA MethylationDown SyndromeFemaleFetusHigh-Throughput Nucleotide SequencingHumansImmunoprecipitationPregnancySequence Analysis, DNABiomarkersDNA

Identifiers

PMID29889893
PMCPMC5995407
OpenAlexW2808479649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.